Pic

Hoth Therapeutics, Inc.

$HOTH
$1.99
Капитализция: $9.6M
Показать больше информации о компании

О компании

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of показать больше
patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy HT-KIT to treat mast-cell derived cancers and anaphylaxis HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis HT-004 for treatment of asthma and allergies using inhalational administration HT-006 to treat lung diseases resulting from bacterial infections and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University the University of Maryland Isoprene Pharmaceuticals, Inc. the North Carolina State University Chelexa BioSciences, Inc. Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy HT-KIT to treat mast-cell derived cancers and anaphylaxis HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis HT-004 for treatment of asthma and allergies using inhalational administration HT-006 to treat lung diseases resulting from bacterial infections and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University the University of Maryland Isoprene Pharmaceuticals, Inc. the North Carolina State University Chelexa BioSciences, Inc. Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Перевод автоматический

показать меньше

Отчетность

03.11.2021, 23:08 EPS за 3 квартал составил ХХ, консенсус YY

04.08.2021, 23:12 Прибыль на акцию за 2 квартал XX, консенсус-прогноз YY
Квартальная отчетность будет доступна после Регистрации

Прогнозы аналитиков

Аналитик Аарон Кесслер поддерживает с сильной покупкой и снижает целевую цену со xxx до yyy долларов.

25.10.2021, 16:02 Аналитик Berenberg Сунил Райгопал инициирует освещение на GoDaddy с рейтингом «Покупать» и объявляет целевую цену в xxx долларов.
Прогнозы аналитиков будут доступны после Регистрации

Все новости компании Hoth Therapeutics

Новости переведены автоматически

Остальные 29 новостей будут доступны после Регистрации

Попробуйте все возможности сервиса Tradesense

Моментальные уведомления об измемении цен акций
Новости с официальных сайтов компаний
Отчётности компаний
События с FDA, SEC
Прогнозы аналитиков и банков
Регистрация в сервисе
Tradesense доступен на мобильных платформах